Xpert Carba-R
  • A rapid diagnostic test that allows doctors to target the right drug for the right patient immediately could save money by reducing the length of stay in a hospital for these patients. Identifying patients with a drug-resistant infection quickly also prevents their infection from being passed on to patients around them because they can be rapidly isolated and infection control measures can be put in place."

    - Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics The Review on Antimicrobial Resistance, Chaired by Jim O’Neill. October 2015

    • Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs.1
    • Organisms carrying integron and plasmid-encoded carbapenemase enzymes are largely responsible for the rapid spread of carbapenem resistance.2
    • CDC recommends comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms.3
    • Current test methods lack the sensitivity, ease of use, and rapid results required to respond quickly to the threat of carbapenemase-producing organisms.

    (1) Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. (http://www.sciencedirect.com/science/article/pii/S0196655316303431); (2) https://wwwnc.cdc.gov/eid/article/17/10/pdfs/11-0655.pdf; (3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf

    Xpert® Carba-R can detect and differentiate the most prevalent carbapenemase gene families in just 48 minutes.

    • Screening* high-risk patients with Xpert Carba-R can alert clinicians and infection preventionists (IPs) rapidly of the presence of gene sequences associated with carbapenem non-susceptibility in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species.
    • Rapid detection and differentiation of the blaKPCblaNDMblaVIMblaOXA-48, and blaIMP gene sequences helps clinicians and IPs to optimize patient management.
      • Comprehensive infection control measures should be applied to patients who are colonized or infected with carbapenemase-producing organisms.3

    *  The CDC recommendations use the term screening synonymously with assessing colonization status. Xpert Carba-R is not indicated for screening.  See Product Insert for complete details.

    (3) http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf

    • Cepheid - The Molecular Diagnostics Leader
    • Dr. Stan Deresinski: CRE & MDR Acinetobacter
    • Dr. Fred Tenover: Carbapenem Resistance: A Medical and Public Health Challenge
    • Catalog #: GXCARBAR-10

      Xpert Carba-R
      Number of Tests: 10

    • How can I place an order?

      Submit your request using our Request Information form, or call 1.888.838.3222, select option 1.